Missed GME or NVDA? Don’t Miss the Next One.​
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CLB Stock Forecast 2025-2026
$10.85
Current Price
$508.68M
Market Cap
Buy 1
Hold 3
Sell 1
Wall St Analyst Ratings
Distance to CLB Price Targets
+121.2%
To High Target of $24.00
+19.8%
To Median Target of $13.00
+1.4%
To Low Target of $11.00
CLB Price Momentum
-8.4%
1 Week Change
-6.5%
1 Month Change
-39.5%
1 Year Change
-37.3%
Year-to-Date Change
-56.8%
From 52W High of $25.13
+7.0%
From 52W Low of $10.14
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Core Lab (CLB) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on CLB and similar high-potential opportunities.
Latest CLB Stock Price Targets & Analyst Predictions
Based on our analysis of 12 Wall Street analysts, CLB has a neutral consensus with a median price target of $13.00 (ranging from $11.00 to $24.00). The overall analyst rating is Buy (6.0/10). Currently trading at $10.85, the median forecast implies a 19.8% upside. This outlook is supported by 1 Buy, 3 Hold, and 1 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CLB Analyst Ratings
1
Buy
3
Hold
1
Sell
CLB Price Target Range
Low
$11.00
Average
$13.00
High
$24.00
Current: $10.85
Latest CLB Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CLB.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 13, 2025 | Citigroup | Scott Gruber | Neutral | Maintains | $13.00 |
| Apr 15, 2025 | Stifel | Stephen Gengaro | Hold | Maintains | $15.00 |
| Mar 12, 2025 | Citigroup | Scott Gruber | Neutral | Upgrade | $16.00 |
| Feb 20, 2025 | Citigroup | Scott Gruber | Sell | Maintains | $15.00 |
| Oct 31, 2024 | Citigroup | Scott Gruber | Sell | Maintains | $14.00 |
| Jul 26, 2024 | Stifel | Stephen Gengaro | Hold | Maintains | $22.00 |
| Jul 15, 2024 | B of A Securities | Chase Mulvehill | Underperform | Maintains | $15.00 |
| Jul 15, 2024 | Piper Sandler | Luke Lemoine | Neutral | Maintains | $17.00 |
| Apr 26, 2024 | Stifel | Stephen Gengaro | Hold | Maintains | $18.00 |
| Apr 15, 2024 | B of A Securities | Chase Mulvehill | Underperform | Maintains | $16.00 |
| Feb 5, 2024 | Stifel | Stephen Gengaro | Hold | Maintains | $17.00 |
| Jan 29, 2024 | Stifel | Stephen Gengaro | Hold | Maintains | $21.00 |
| Sep 18, 2023 | Citigroup | Scott Gruber | Sell | Maintains | $20.00 |
| Jul 31, 2023 | Piper Sandler | Luke Lemoine | Neutral | Maintains | $21.00 |
| Jun 30, 2023 | Citigroup | Scott Gruber | Sell | Downgrade | $21.00 |
| May 1, 2023 | Piper Sandler | Luke Lemoine | Neutral | Maintains | $19.00 |
| Apr 28, 2023 | Stifel | Stephen Gengaro | Hold | Maintains | $25.00 |
| Apr 18, 2023 | B of A Securities | Chase Mulvehill | Underperform | Downgrade | $21.50 |
| Feb 7, 2023 | Citigroup | Scott Gruber | Neutral | Maintains | $26.00 |
| Jan 9, 2023 | B of A Securities | Chase Mulvehill | Neutral | Upgrade | $0.00 |
Core Laboratories Inc. (CLB) Competitors
The following stocks are similar to Core Lab based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Core Laboratories Inc. (CLB) Financial Data
Core Laboratories Inc. has a market capitalization of $508.68M with a P/E ratio of 18.4x. The company generates $517.80M in trailing twelve-month revenue with a 5.4% profit margin.
Revenue growth is -4.7% quarter-over-quarter, while maintaining an operating margin of +6.3% and return on equity of +11.6%.
Valuation Metrics
Market Cap
$508.68M
Enterprise Value
$675.82M
P/E Ratio
18.4x
PEG Ratio
11.1x
Price/Sales
1.0x
Growth & Margins
Revenue Growth (YoY)
-4.7%
Gross Margin
+16.5%
Operating Margin
+6.3%
Net Margin
+5.4%
EPS Growth
-4.7%
Financial Health
Cash/Price Ratio
+4.4%
Current Ratio
2.2x
Debt/Equity
69.4x
ROE
+11.6%
ROA
+5.3%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Core Laboratories Inc. (CLB) Business Model
About Core Laboratories Inc.
What They Do
Provides oil and gas reservoir optimization services.
Business Model
The company operates by offering specialized services that enhance the production capabilities of oil and gas reserves. It generates revenue through advanced technology applications in fluid analysis, PVT testing, and core analysis, which are critical for optimizing hydrocarbon extraction and resource management.
Additional Information
Core Laboratories is headquartered in Amsterdam and operates in key energy-producing regions globally. The company emphasizes innovation and sustainability, helping energy producers navigate the evolving challenges in the energy sector.
Company Information
Sector
Energy
Industry
Oil & Gas Equipment & Services
Employees
3,400
CEO
Mr. Lawrence V. Bruno
Country
United States
IPO Year
1995
Website
www.corelab.comCore Laboratories Inc. (CLB) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Why Is Core Laboratories (CLB) Down 5.9% Since Last Earnings Report?
Core Laboratories (CLB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
May 23, 2025
By Zacks Equity Research
Realtime BLOG
Core Laboratories Down 30% YTD: Should You Hold or Sell the Stock?
CLB struggles with a 4.4% revenue decline, low ROIC in the first quarter of 2025, minimal dividends and vulnerability to oil price volatility and geopolitical instability.
May 15, 2025
By Zacks Equity Research
Analyst Blog
Latest News
Quick Summary
CLB reported a 4.4% revenue decline and low ROIC in Q1 2025, with minimal dividends and exposure to oil price fluctuations and geopolitical risks.
Why It Matters
CLB's revenue drop and low ROIC indicate financial weakness, raising concerns about profitability and stability, especially amid oil price volatility and geopolitical risks.
Source: Zacks Investment Research
Market Sentiment:
Negative
New Strong Sell Stocks for May 14th
10 days ago
Quick Summary
AMTB, CLB, and EXPI were added to the Zacks Rank #5 (Strong Sell) List on May 14, 2025, indicating a negative outlook for these stocks.
Why It Matters
AMTB, CLB, and EXPI being added to the Zacks Rank #5 indicates a potential decline in their stock performance, signaling higher risk for investors holding or considering these stocks.
Source: Zacks Investment Research
Market Sentiment:
Negative
CORE LABORATORIES ANNOUNCES OPENING OF UNCONVENTIONAL CORE ANALYSIS LABORATORY IN SAUDI ARABIA
16 days ago
Quick Summary
Core Laboratories Inc. opened a new Unconventional Core Analysis Laboratory in Dammam, Saudi Arabia, in partnership with Abdulla Fouad Group, enhancing its reservoir evaluation technologies in the region.
Why It Matters
The new laboratory enhances Core Laboratories' capabilities in a key oil market, potentially increasing revenue and market share, which can positively impact stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Core Laboratories Inc. will hold its Q1 2025 Earnings Conference Call on April 24, 2025, at 8:30 AM ET, featuring key executives including CEO Larry Bruno and CFO Chris Hill.
Why It Matters
Core Laboratories' Q1 earnings call provides insights into financial performance, strategic direction, and market conditions, impacting investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
CORE LAB REPORTS FIRST QUARTER 2025 RESULTS
1 month ago
Quick Summary
Core Laboratories Inc. reported Q1 2025 revenue of $123.6M, down 4% sequentially and 5% YoY. Operating income was $4.4M, EPS at $0.00. Free cash flow increased 50% YoY to $3.9M.
Why It Matters
Declining revenue and EPS signal potential weaknesses in Core Laboratories' performance, impacting investor confidence. However, improved free cash flow and reduced net debt may attract cautious investors.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Core Laboratories (CLB) reported quarterly earnings of $0.14 per share, missing the Zacks Consensus Estimate of $0.15 and down from $0.19 per share a year earlier.
Why It Matters
Core Laboratories' earnings miss signals potential operational challenges and declining profitability, which may impact investor confidence and stock performance.
Source: Zacks Investment Research
Market Sentiment:
Negative
Frequently Asked Questions About CLB Stock
What is Core Laboratories Inc.'s (CLB) stock forecast for 2025?
Based on our analysis of 12 Wall Street analysts, Core Laboratories Inc. (CLB) has a median price target of $13.00. The highest price target is $24.00 and the lowest is $11.00.
Is CLB stock a good investment in 2025?
According to current analyst ratings, CLB has 1 Buy ratings, 3 Hold ratings, and 1 Sell ratings. The stock is currently trading at $10.85. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CLB stock?
Wall Street analysts predict CLB stock could reach $13.00 in the next 12 months. This represents a 19.8% increase from the current price of $10.85. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Core Laboratories Inc.'s business model?
The company operates by offering specialized services that enhance the production capabilities of oil and gas reserves. It generates revenue through advanced technology applications in fluid analysis, PVT testing, and core analysis, which are critical for optimizing hydrocarbon extraction and resource management.
What is the highest forecasted price for CLB Core Laboratories Inc.?
Price targets from Wall Street analysts for CLB are not currently available. The stock is trading at $10.85.
What is the lowest forecasted price for CLB Core Laboratories Inc.?
Price targets from Wall Street analysts for CLB are not currently available. The stock is trading at $10.85.
What is the overall CLB consensus from analysts for Core Laboratories Inc.?
The overall analyst consensus for CLB is neutral. Out of 12 Wall Street analysts, 1 rate it as Buy, 3 as Hold, and 1 as Sell, with a median price target of $13.00.
How accurate are CLB stock price projections?
Stock price projections, including those for Core Laboratories Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 24, 2025 4:22 AM UTC